Study of GS-0151 in Participants With Rheumatoid Arthritis
← catalyst calendarNCT06902519 · readout ≤ 224 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
75estimated
Sites
35
Countries
Georgia, Germany, Moldova +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-14 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Interventions
- Drug: GS-0151
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFCohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
measured First dose up to 19 Weeks post end of treatment at Week 12
Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
measured First dose up to 19 Weeks post end of treatment at Week 12
Cohorts 1, 2 and 3: Percentage of Participants Experiencing Serous Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study Discontinuation
measured First dose up to 19 Weeks post end of treatment at Week 12
Cohort 1, 2 and 3: Serum AUCtau Following the Last Dose of GS-0151
measured Up to Week 12
Cohorts 1, 2 and 3: Serum Cmax, Following the Last Dose of GS-0151
measured Up to Week 12
Cohorts 1, 2 and 3: Serum Tmax Following the Last Dose of GS-0151
measured Up to Week 12
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed